Background: British 5-year survival from colorectal cancer (CRC) is below the European average, but the reasons are unclear. This study explored if longer provider delays (time from presentation to treatment) were associated with more advanced stage disease at diagnosis and poorer survival.
others have failed to demonstrate that delays influence stage at diagnosis and survival in CRC (Wattercheril et al, 2008; Iversen et al, 2009; Simunovic et al, 2009; Terhaar sive Droste et al, 2010) . The methodological rigour of existing studies is sub-optimal, however, paying scant attention to important patient and tumour characteristics and treating the effect of time to treatment on disease stage and survival as linear. More recent work from Denmark concludes that it is not (Tørring et al, 2011 (Tørring et al, , 2012 . These studies, which are strengthened by clearer definitions of the delays experienced by patients in the diagnosis and treatment of cancer, found a non-monotonic relationship between provider delay and 3-year mortality from colorectal cancer (Weller et al, 2012; Tørring et al, 2011 Tørring et al, , 2012 . In the Danish study, survival was poorest among those treated most rapidly, improving briefly as time to diagnosis increased, before deteriorating again after a few weeks. This suggested that delays before diagnosis are important if an initial poor prognostic group with aggressive disease is excluded. The authors, however, had limited scope to adjust for factors associated with aggressive disease, such as tumour grade or symptoms and signs at presentation.
The present study explored whether patients with longer times between first presentation in primary care and treatment (provider delay) had more advanced stage at diagnosis and poorer survival for CRC when important confounders such as tumour grade and symptoms and signs were taken into account.
MATERIALS AND METHODS
Data were linked from four datasets. The CRUX (Comparing Rural and Urban Cancer Care) dataset, collected in 2000 and 2001, provides primary care data on people diagnosed in Northern Scotland with CRC between 1997 and 1998 (Robertson et al, 2004) . Data includes details of consultations with relevant symptoms and signs before diagnosis (Scottish Intercollegiate Guideline Network (SIGN), 2003; Robertson et al, 2004) . Date of first presentation in primary care was the first record of a relevant sign or symptom of CRC preceding diagnosis. Subsequently dates of first hospital referral, diagnosis, and first treatment were recorded. Patients with symptoms and signs for 42 years before treatment were excluded. This dataset was linked to the Scottish Cancer Registry to obtain modified Dukes' stage and tumour grade (Brewster et al, 2002; Brewster and Stockton, 2008) . Further linkage was made to the General Register Office for Scotland Death Registry (for date of death, primary and secondary causes), and SMR01, an episodebased record of all discharges from Scottish hospitals (Kendrick and Clarke, 1993; Kendrick, 1997) . The Scottish Cancer Registry and CRUX datasets were linked directly using the Scottish Cancer Registry ID number. The SMR01 and death records were linked using computerised probability linkage (Harley and Jones, 1996) . Linkage was performed at ISD Scotland, the final dataset supplied as an SPSS (IBM SPSS Statistics for Windows, Version 20.0, IBM Corp, Armonk, NY, USA) datafile with all personal identifying information removed.
Statistical analysis. The two main outcomes were stage at diagnosis (Dukes A, B, C or D) and all cause survival from date of first presentation in primary care. Survival was measured from date of presentation rather than date of diagnosis or treatment to overcome lead-time bias. A sensitivity analysis was also conducted measuring survival from date of diagnosis or treatment and is presented as Supplementary Note 1.
The main predictor variable was defined as time from first presentation in primary care to first treatment or to definitive diagnosis as recorded in the Scottish Cancer Registry if no treatment was given. A range of potential confounders were available including tumour site, stage at diagnosis, grade of differentiation, place of presentation, specific symptoms and signs at presentation, type of admission (emergency or elective), age, gender, smoking status, Carstairs deprivation quintile and Charlson co-morbidity index (Charlson et al, 1987; Morris and Carstairs, 1991) .
Data were analysed using Stata (Version 11; StataCorp, College Station, TX, USA). Provider delay (time from first presentation in primary care to treatment) was converted into weeks and treated as a continuous variable. Stage was collapsed into a binary variable (early (A or B) vs advanced (C or D)). A stringent P-valuep0.01 was used to denote statistical significance throughout the analysis. This was chosen to minimise the chance of a Type 1 error arising from multiple testing. To explore the relationship between provider delay and stage at diagnosis, logistic regression was used. An unadjusted odds ratio (OR) and 99% confidence interval (CI) for provider delay (weeks) was calculated and three sequentially adjusted models were run. Potential confounders were those that were deemed to be clinically important and/or showed a univariate relationship with outcome at a conservative Pp0.10. In model 2, age, smoking status, Carstairs deprivation quintile, Charlson co-morbidity index and place of presentation were included. Model 3 added tumour grade and type of hospital admission, while model 4 further added a range of symptoms and signs (constipation, rectal bleeding, abdominal pain, anorexia, weight loss and abdominal mass).
Cox survival analysis was used to examine the relationship between provider delay and mortality with hazard ratios (HRs) and 99% CIs being calculated. As before, four sequential models were fitted adjusting for patient factors, tumour grade and type of hospital admission, symptoms and signs. The proportional hazard assumption is based on Schoenfeld residuals (no violations were detected in the current analyses) (Hess, 1995) .
To model the nonlinear relationship between provider delay and either stage or mortality, a restricted cubic spline (RCS) procedure was adopted (Dupout, 2008) . This uses multiple polynomial line segments within the range of provider delay, the boundaries of these line segments being called knots. Knots are placed at equally spaced centiles of the distribution of provider delay. In the current analyses, five knots were considered and placed at the 0th, 25th, 50th, 75th and 100th percentile points of provider delay. A spline function was assumed to be significant if the P-value for the model w 2 was p0.01 and the association is assumed to be nonlinear if the spline coefficients differ significantly from each other based on the Wald test for linearity. A provider delay value of 4 weeks was used as the reference value to estimate odds of late stage disease in the logistic RCS analyses and the HR of mortality in the RCS Cox analyses. A further stratified analysis of the relationship between provider delay, stage and mortality was conducted treating colonic and rectal tumours separately (Supplementary Note 2).
RESULTS
A total of 958 patients with symptomatic CRC were included in the survival analysis. Of 958 patients, 868 had data on stage (Table 1) . The median (IQR) provider delay was 17 (8-39) weeks. Over half the cohort was male (56.6%), the mean (s.d.) age was 69.9 (10.8) years and over 75% of patients were in the three least deprived quintiles.
Stage as the outcome. In univariate logistic regression analysis, younger age, co-morbidities and higher grade tumours were significant predictors of advanced stage (Table 1) . Table 2 presents the results of the logistic RCS analyses to explore the association of provider delay on advanced stage at diagnosis. In the fully adjusted model 4, provider delay of 40 and 60 weeks was associated with later stage disease at presentation, but the ORs did not reach statistical significance. In addition, older age was associated with earlier stage disease, whereas higher grade tumours and a higher Charlson co-morbidity index were independently associated with more advanced stage. The nonlinear relationship between provider delay and stage are illustrated by the spline curves shown in Figures 1 and 2. These curves plot the length of the provider delay on the X-axis against the odds of patients having later stage disease on the Y-axis. Figure 1 shows the spline curves for each of the four sequential models from the unadjusted model (solid line) through varying degrees of adjustment to the fully adjusted model (long dash dotted line). Overall, provider delay was significantly associated with stage in the unadjusted model (P ¼ 0.002) and the P-value for the nonlinear association was P ¼ 0.04. Treatment delays between 4 and 34 weeks (with the lowest OR occurring at 20 weeks) were associated with earlier stage. Treatment delays beyond this were associated with more advanced disease at diagnosis, although the odds began to diminish again after about 1 year. Adjusting for confounders reduced the odds of advanced disease for those with short delays, but had little other impact. Figure 2 shows the fully adjusted model of provider delay on odds (99% CI) of late stage disease after adjustment for patient and tumour factors, emergency admissions and symptoms and signs. The CIs were wide such that there did not appear to be a strong relationship between provider delay and stage of CRC at diagnosis after multi-adjustment. The analysis of the relationship between provider delay and stage for colonic and rectal tumours separately lacked statistical power, but provided no real evidence of any difference between the two cancer sites (Supplementary Note 2).
Mortality as the outcome. In univariate survival analysis, older age, a higher Charlson co-morbidity index, higher grade tumours, presentation through a general practitioner home visit, emergency admission and the symptom anorexia were each associated with a significantly increased hazard of mortality (Table 3) . Table 4 presents the results of the sequential Cox survival analyses. In the fully adjusted model, age, male gender, a higher Charlson co-morbidity index, higher tumour grade and the symptoms and signs of anorexia and abdominal mass were each independently associated with an increased hazard of mortality. In the unadjusted model, provider delay was inversely associated with mortality (Po0.001) and the association was nonlinear (Po0.001). Figure 3 displays separate spline curves for each of the four survival models, illustrating the effect of sequential adjustment for potential confounders. In the unadjusted model, treatment delays o4 weeks were associated with poor survival, but this association was no longer present after adjusting for confounders. An initial U-shaped survival curve in the unadjusted model (with lowest HR at B16 weeks) became less pronounced with sequential adjustment. Figure 4 shows the spline curve for the fully adjusted model along with the 99% CIs. For people with CRC, after simultaneous adjustment for patient factors, tumour factors and symptoms, longer provider delay was not significantly associated with survival from CRC. Due to smaller numbers, the analysis of the relationship between provider delay and mortality for colonic and rectal tumours separately lacked statistical power, but provided no real evidence of any difference between the two cancer sites (Supplementary Note 2).
DISCUSSION
Summary of main findings. We have confirmed that there is a nonlinear relationship between time before treatment and both disease stage and survival. Colorectal cancer patients with very short provider delays have a poor prognosis explained by their personal characteristics and features of the tumour, including grade and symptoms. These patients apart, however, we have not found that longer provider delays are associated with poorer survival. In both analyses, CIs were wide so the possibility of long provider delays having deleterious effects on stage at diagnosis and survival cannot be excluded. However, any true effect from provider delay on CRC outcome seems likely to be small in population terms, certainly when compared with patient delays which are likely to have a much greater role (Simon et al, 2010) . When explored separately, there appeared to be no obvious difference in the relationship between provider delay, mortality and stage between colonic or rectal tumours.
Strengths and limitations.
Some limitations of the current analyses should be acknowledged. An historical sample (patients diagnosed with symptomatic CRC between 1997 and 1998) was used predating important changes in management, and it is important to emphasise that the patterns of delays experienced by patients may be different now. For example, bowel screening will increase the proportion of people diagnosed pre-symptomatically, although fewer than 15% of CRC cases in Scotland since 2007 were screen detected (Information and Statistics Division (ISD), 2013). Treatment has also improved since 1998, particularly more widespread adjuvant chemotherapy, and pre-operative radiotherapy in rectal cancer. Both advances, however, may even further attenuate any relationship between provider delay and outcome. It does not seem likely that there will have been important changes in the biology of CRC in that time, but the possibility should not be discounted out-of-hand. Most importantly, while our results provide reassurance, they should not engender complacency. The quality of clinical data continues to improve along with scope to link those data from primary care, secondary care and national registries. The methods reported here should be replicated using increasingly detailed and sophisticated linked clinical datasets so that knowledge on the relationship between delay and outcome continues to accumulate. This was an observational retrospective study dependent on good quality data within primary care-held medical records. For those presenting a long time before treatment, their initial symptoms and signs may have been due to other causes, which may account for falling odds of late stage disease and improving survival observed with provider delays of more than a year. There are, however, several strengths to the analysis. This was a population-based sample, including all patients diagnosed within the study period and not limited to those treated within tertiary cancer centres. The sample was large with high levels of complete follow-up and was effectively linked to high quality routine datasets. The extent of the data enabled a detailed analysis adjusting for a greater array of potential explanatory variables than previously. Our choice of variables included in the regression model was pragmatic. Tumour stage as a predictor variable was excluded from the multivariate survival models since, if time between presentation and treatment is an important factor for survival, then its effect would be via more advanced disease stage. In contrast, tumour grade is less likely to be on the causal pathway since it is an intrinsic biological feature of the tumour less likely to be affected by provider delay. Symptoms and signs are complex, but, like emergency admission and place of presentation, are more likely to be markers of disease progression than intermediate variables. Hence, adjustment for grade, symptoms and signs, emergency admissions and place of presentation was performed since they may be markers for the more biologically aggressive tumours believed to produce 'waiting time paradox' of poorest outcome for those with shortest delays (Neal, 2009 ).
Context with other literature. In 2011, a Danish group addressed several methodological weaknesses in earlier work by analysing diagnostic delay in CRC as both a categorical and continuous variable using RCSs. (Tørring et al, 2011) . They analysed patients with alarm symptoms separately from those with vague symptoms. Patients with vague symptoms did not have better survival, causing the authors to dispute the usual interpretation of the waiting time paradox (i.e, the most biologically aggressive tumours are diagnosed most quickly) since in this case, patients with vague Place of presentation symptoms and signs would have better overall survival. Instead, they argued that the waiting time paradox is produced when doctors expedite investigation and treatment of patients with dramatic symptoms (i.e, those that have waited the longest to present) and consequently a poorer prognosis. In patients presenting with alarm symptoms, those with the shortest diagnostic intervals had the poorest prognosis with 3-year mortality dropping initially, but then climbing after 6 weeks, a U-shaped curve. In contrast, for patients with vague symptoms, the risk of 3-year mortality climbed from day 1 to week 12, although the relationship was not statistically significant. The authors concluded that the diagnostic interval does matter, especially in patients without alarm symptoms. Our unadjusted mortality analysis produced a similar curve, but once we adjusted for several prognostic factors, not available to the Danish investigators, which may confound the relationship between provider delay, stage-atpresentation and mortality, the initial sharp downswing of the U flattens out, as does the later upswing. This suggests that these factors that are linked to tumour biology are more influential than provider delays. The Danish investigators based their survival analysis on survival from date of diagnosis, rather than date of first presentation in primary care. For this reason we have also performed a sensitivity analysis, where we have analysed survival from date of treatment (or definitive diagnosis as recorded in the Scottish Cancer Registry if no treatment). This has not appreciably affected our results, interpretations or conclusions. A further study by the same authors combined data from two Danish datasets and one UK dataset (n ¼ 1243) finding a similar U-shaped association between mortality and diagnostic delay (Tørring et al, 2012) . Their combined results again support the assertion that longer diagnostic intervals cause higher mortality in patients with CRC, but again without accounting for many important potential confounders (Tørring et al, 2012) . Notably this paper included a cohort from the UK, where survival began to decline after B15 weeks, the same approximate relationship observed in our unadjusted mortality analysis.
The current approach has incorporated the methodological recommendations of Tørring et al (2011) , but the nature of our dataset has permitted a more complete and detailed adjustment for particular symptoms and signs at diagnosis. Employing this approach, we believe, our analysis is less at risk from confounding.
Conclusions and implications. Prolonged provider delays before assessment cause people who may have cancer, and their families, anxiety and worry. Anxiety may be heightened by the commonly held view that provider delays of even a few weeks can adversely affect outcomes. In this sample of people diagnosed with CRC between 1997 and 1998 longer provider delays did not lead to poorer survival. While long delays are obviously undesirable, the imposition of tight cancer waiting times targets could curtail intensive preparation for major surgery, meaning resources are not being used to support the best potential outcomes of treatment (Tønnesen et al, 2009) . There is also the risk that such efforts divert research and resource from increasing public awareness of cancer systems and reducing patient delays, which are generally agreed to have greater impact on cancer outcomes (Simon et al, 2010) . Currently, the NHS prioritises waiting time targets and they are measured by the government with adverse publicity if they are not achieved. In turn, publicity around targets may, inadvertently, increase anxiety experienced by patients and relatives by reinforcing the unjustified belief that even modest delays impact on survival. Whether the current emphasis on awareness and early diagnosis in the UK will have any appreciable impact on reducing premature mortality from CRC remains to be proven, especially when compared with the biology of the underlying cancer, delays might be less important to outcome than is commonly believed. 2011 by the Privacy Advisory Committee of ISD Scotland. Following discussion with the North of Scotland Research Ethics Committee it was decided on 7 February 2011 that formal ethical approval was not required. Research and Development approval was granted from NHS Grampian on 14 June 2011. The University of Aberdeen acted as sponsor for the study.
